Picture this: someone at a funeral whispers, “But if they’re cremated... how will they rise on Judgment Day?” Suddenly you’re side-eyeing the urn like it just became a theological problem. This ...

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital ...

A New York doctor who treated HIV and AIDS patients sued Gilead for violating the False Claims Act with payments to doctors who spoke at sponsored events.

Aside from Gilead, American depositary shares of GSK fell 2.18% in early trading. The multinational biopharma firm is a majority owner of the HIV-focused company Viiv.

Gilead's dominance in HIV faces Medicare pricing challenges, limiting growth.

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment ...

Take a spin through the latest in Gilead’s science and innovation in our new series, The Centrifuge Sessions.

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech stock.

Cognizant, an IT consulting firm, announced it is expanding its existing relationship with biopharmaceutical company Gilead Sciences to deliver better cost leadership and productivity enhancement for ...